Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2007 Annual Meeting of the American Society of Hematology (ASH) to be held December 8-11, 2007 at the Georgia World Congress Center in Atlanta, Georgia. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration with GlaxoSmithKline.
